{"title":"卵巢癌生物标志物:早期诊断的进展","authors":"Zeba Mueed, P. Rai, S. Siddique, N. Poddar","doi":"10.2174/2212796815666210121095445","DOIUrl":null,"url":null,"abstract":"\n\nThe advancements in cancer treatment have no significant effect on\novarian cancer [OC]. The lethality of the OC remains on the top list of gynecological\ncancers. The long term survival rate of the OC patients with the advanced\nstage is less than 30%. The only effective measure to increase the survivability\nof the patient is the detection of disease in stage I. The earlier the diagnosis, the\nmore will be the chances of survival of the patient. But due to the absence of\nsymptoms and effective diagnosis, only a few % of OC are detected in stage I. A\nvalid, reliable having a high acceptance test is imperative to detect OC in its early\nstages. Currently, the most used approach for the detection of OC is the screening\nof CA-125 and transvaginal ultrasonography together. This approach has an\nefficacy of only 30-45%. A large number of biomarkers are also being explored\nfor their potential use in the early screening of OC, but no success is seen so far.\nThis review provides an overview of the biomarkers being explored for early-stage\ndiagnosis of OC and increasing the current long-term survival rates of OC\npatients.\n","PeriodicalId":10784,"journal":{"name":"Current Chemical Biology","volume":"20 1","pages":"109-125"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Ovarian Cancer Biomarkers: Headway Towards Early Diagnosis\",\"authors\":\"Zeba Mueed, P. Rai, S. Siddique, N. Poddar\",\"doi\":\"10.2174/2212796815666210121095445\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n\\nThe advancements in cancer treatment have no significant effect on\\novarian cancer [OC]. The lethality of the OC remains on the top list of gynecological\\ncancers. The long term survival rate of the OC patients with the advanced\\nstage is less than 30%. The only effective measure to increase the survivability\\nof the patient is the detection of disease in stage I. The earlier the diagnosis, the\\nmore will be the chances of survival of the patient. But due to the absence of\\nsymptoms and effective diagnosis, only a few % of OC are detected in stage I. A\\nvalid, reliable having a high acceptance test is imperative to detect OC in its early\\nstages. Currently, the most used approach for the detection of OC is the screening\\nof CA-125 and transvaginal ultrasonography together. This approach has an\\nefficacy of only 30-45%. A large number of biomarkers are also being explored\\nfor their potential use in the early screening of OC, but no success is seen so far.\\nThis review provides an overview of the biomarkers being explored for early-stage\\ndiagnosis of OC and increasing the current long-term survival rates of OC\\npatients.\\n\",\"PeriodicalId\":10784,\"journal\":{\"name\":\"Current Chemical Biology\",\"volume\":\"20 1\",\"pages\":\"109-125\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Chemical Biology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/2212796815666210121095445\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Chemical Biology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/2212796815666210121095445","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Ovarian Cancer Biomarkers: Headway Towards Early Diagnosis
The advancements in cancer treatment have no significant effect on
ovarian cancer [OC]. The lethality of the OC remains on the top list of gynecological
cancers. The long term survival rate of the OC patients with the advanced
stage is less than 30%. The only effective measure to increase the survivability
of the patient is the detection of disease in stage I. The earlier the diagnosis, the
more will be the chances of survival of the patient. But due to the absence of
symptoms and effective diagnosis, only a few % of OC are detected in stage I. A
valid, reliable having a high acceptance test is imperative to detect OC in its early
stages. Currently, the most used approach for the detection of OC is the screening
of CA-125 and transvaginal ultrasonography together. This approach has an
efficacy of only 30-45%. A large number of biomarkers are also being explored
for their potential use in the early screening of OC, but no success is seen so far.
This review provides an overview of the biomarkers being explored for early-stage
diagnosis of OC and increasing the current long-term survival rates of OC
patients.
期刊介绍：
Current Chemical Biology aims to publish full-length and mini reviews on exciting new developments at the chemistry-biology interface, covering topics relating to Chemical Synthesis, Science at Chemistry-Biology Interface and Chemical Mechanisms of Biological Systems. Current Chemical Biology covers the following areas: Chemical Synthesis (Syntheses of biologically important macromolecules including proteins, polypeptides, oligonucleotides, oligosaccharides etc.; Asymmetric synthesis; Combinatorial synthesis; Diversity-oriented synthesis; Template-directed synthesis; Biomimetic synthesis; Solid phase biomolecular synthesis; Synthesis of small biomolecules: amino acids, peptides, lipids, carbohydrates and nucleosides; and Natural product synthesis).
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
